Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 2Phase 1/2 2Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 119HER2-positive Breast Cancer 10Stomach Neoplasms 9Neoplasm Metastasis 6Neoplasms 4Inflammatory Breast Neoplasms 4Esophageal Neoplasms 3Adenocarcinoma Of Esophagus 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Invasive Breast Cancer 2HER2-positive Metastatic Breast Cancer 2HER2-positive Early Breast Cancer 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Solid Tumors 1Resectable HER2-positive Breast Cancer 1Patient Preference 1Pathologic Complete Response 1Osteitis Deformans 1Metastatic HER2-positive Breast Cancer 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Gastric Cancer 1HER2-positive Carcinoma of Breast 1HER2-positive Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Early or Locally Advanced Breast Cancer 1HER2 Positive Early Breast Cancer 1Endometrial Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

Paclitaxel 25Doxorubicin 15Carboplatin 14pembrolizumab 10Cisplatin 8Radiotherapy 6Docetaxel 5Chemotherapy, Adjuvant 5Taxes 4Filgrastim 4Brachytherapy 4lenvatinib 3Observation 3trastuzumab deruxtecan 2selinexor 2olaparib 2durvalumab 2Tamoxifen 2Specimen Handling 2Ifosfamide 2Drug Therapy 2sintilimab 1sacituzumab govitecan 1pertuzumab 1nanocis 1liposomal doxorubicin 1ixabepilone 1gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1dostarlimab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Endometrial Neoplasms × Trastuzumab × Clear all
NCT05256225 2026-05-27

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡